Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Cancer-therapy-related cardiotoxicity (CTRCT) is a significant and frequent complication of monoclonal antibody-directed therapy, especially Trastuzumab, for human epidermal growth factor receptor 2 (HER2) overexpressing breast cancers. Reliable, clinically available molecular predictive markers of CTRCT have not yet been developed. |